Active ingredientsDosage formQuantity of active ingredientsShortage statusAvailabilityReasonLast updated
| clevidipine | Injection, emulsion | 25 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 20/02/2026 |
| hydrochlorothiazide~candesartan cilexetil | Tablet, uncoated | 12.5 mg~16 mg | Resolved | Available | Manufacturing | 20/02/2026 |
| paracetamol~codeine phosphate hemihydrate | Tablet, uncoated | 500 mg~30 mg | Current | Limited Availability | Manufacturing | 20/02/2026 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Limited Availability | Manufacturing | 20/02/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 20/02/2026 |
| naltrexone hydrochloride | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 20/02/2026 |
| Teriparatide | Injection, solution | .25 mg/mL | Current | Limited Availability | Manufacturing | 20/02/2026 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 20/02/2026 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 20/02/2026 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~20 mg | Current | Unavailable | Manufacturing | 20/02/2026 |
| trandolapril | Capsule | 4 mg | Current | Unavailable | Manufacturing | 20/02/2026 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 20/02/2026 |
| ondansetron | Tablet, orally disintegrating | 4 mg | Resolved | Available | Manufacturing | 20/02/2026 |
| ropinirole hydrochloride | Tablet, film coated | .285 mg | Current | Unavailable | Manufacturing | 20/02/2026 |
| gliclazide | Tablet, modified release | 30 mg | Anticipated | Available | Manufacturing | 20/02/2026 |
| finasteride | Tablet, film coated | 1 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 20/02/2026 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Limited Availability | Manufacturing | 20/02/2026 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 27 mg~100 mg | Anticipated | Available | Manufacturing | 20/02/2026 |
| ethinylestradiol~norethisterone | Tablet, uncoated | 36 microgram~500 microgram | Resolved | Available | Manufacturing | 20/02/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 582.21 mg | Current | Unavailable | Manufacturing | 20/02/2026 |
| hydrocortisone sodium succinate | Injection, powder for | 334.25 mg | Anticipated | Available | Manufacturing | 20/02/2026 |
| Thyrotropin alfa | Injection, powder for | 1.1 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 20/02/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Resolved | Available | Manufacturing | 20/02/2026 |
| aripiprazole | Tablet, uncoated | 15 mg | Current | Limited Availability | Manufacturing | 20/02/2026 |
| finasteride | Tablet, film coated | 1 mg | Current | Limited Availability | Unexpected increase in consumer demand | 20/02/2026 |
| linezolid | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 20/02/2026 |
| sodium valproate | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 20/02/2026 |
| mirtazapine | Tablet, film coated | 15 mg | Current | Limited Availability | Manufacturing | 20/02/2026 |
| nizatidine | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 20/02/2026 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Current | Limited Availability | Unexpected increase in consumer demand | 20/02/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Manufacturing | 19/02/2026 |
| galantamine~galantamine hydrobromide | Capsule, modified release | 16 mg~20.51 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 19/02/2026 |
| ezetimibe~simvastatin | Tablet | 10 mg~40 mg | Current | Limited Availability | Manufacturing | 19/02/2026 |
| voriconazole | Tablet, film coated | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/02/2026 |
| nicorandil | Tablet, uncoated | 10 mg | Resolved | Available | Manufacturing | 19/02/2026 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 30.76 mg~24 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 19/02/2026 |
| fingolimod hydrochloride | Capsule | 560 microgram | Current | Unavailable | Manufacturing | 19/02/2026 |
| crisaborole | Ointment | 2 % w/w | Anticipated | Available | Unexpected increase in consumer demand | 19/02/2026 |
| dinoprostone | Gel | .3333 mg/g | Current | Unavailable | Manufacturing | 19/02/2026 |
| sodium amidotrizoate~amidotrizoate meglumine | Injection, intravenous infusion | 40 mg/mL~260 mg/mL | Current | Unavailable | Product recall | 19/02/2026 |
| simvastatin~ezetimibe | Tablet | 80 mg~10 mg | Current | Limited Availability | Manufacturing | 19/02/2026 |
| Mecasermin | Injection, solution | 10 mg/mL | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 19/02/2026 |
| cytarabine | Injection, solution | 100 mg/mL | Resolved | Available | Manufacturing | 19/02/2026 |
| terbinafine hydrochloride | Tablet, uncoated | 281.25 mg | Current | Unavailable | Manufacturing | 19/02/2026 |
| dinoprostone | Gel | .6667 mg/g | Current | Unavailable | Manufacturing | 19/02/2026 |
| amlodipine besilate~telmisartan | Tablet, film coated | 6.935 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 19/02/2026 |
| amlodipine besilate~telmisartan | Tablet, film coated | 13.87 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 19/02/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Resolved | Available | Manufacturing | 19/02/2026 |
| amidotrizoate meglumine~sodium amidotrizoate | Oral Liquid, solution | 66 g~10 g | Current | Unavailable | Product recall | 19/02/2026 |
| galantamine hydrobromide | Capsule, modified release | 10.256 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 18/02/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 18/02/2026 |
| vinorelbine tartrate | Injection, concentrated | 13.85 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 18/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 20 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 18/02/2026 |
| Paper wasp venom | Injection, powder for | 550 microgram | Current | Unavailable | Manufacturing | 18/02/2026 |
| propofol | Injection, intravenous infusion | 10 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 18/02/2026 |
| pantoprazole sodium sesquihydrate | Tablet, enteric coated | 22.7 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 18/02/2026 |
| amisulpride | Tablet | 200 mg | Resolved | Available | Manufacturing | 18/02/2026 |
| olanzapine | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 18/02/2026 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 18/02/2026 |
| esomeprazole sodium | Injection, powder for | 42.5 mg | Anticipated | Available | Manufacturing | 18/02/2026 |
| Albumin | Injection | .3 mg/mL | Current | Unavailable | Manufacturing | 18/02/2026 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 18/02/2026 |
| glyceryl trinitrate | Drug delivery system, transdermal | 18 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 18/02/2026 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 18/02/2026 |
| clindamycin phosphate | Cream | 22.8 mg/g | Anticipated | Available | Unexpected increase in consumer demand | 18/02/2026 |
| Interferon gamma1b | Injection, solution | 4 million IU/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 18/02/2026 |
| daunorubicin hydrochloride | Injection, powder for | 20 mg | Current | Limited Availability | Manufacturing | 17/02/2026 |
| sodium amidotrizoate~amidotrizoate meglumine | Injection, solution | 40 mg/mL~260 mg/mL | Current | Unavailable | Manufacturing | 17/02/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 17/02/2026 |
| etoposide phosphate | Injection, powder for | 1136 mg | Resolved | Available | Manufacturing | 17/02/2026 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 17/02/2026 |
| mirtazapine | Tablet, film coated | 15 mg | Current | Limited Availability | Manufacturing | 17/02/2026 |
| tadalafil | Tablet, film coated | 20 mg | Anticipated | Available | Manufacturing | 17/02/2026 |
| levodopa~carbidopa monohydrate | Tablet, uncoated | 100 mg~26.9 mg | Current | Limited Availability | Manufacturing | 17/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 400 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/02/2026 |
| midazolam | Injection, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 17/02/2026 |
| acetazolamide sodium | Injection, powder for | 549.5 mg | Current | Unavailable | Manufacturing | 17/02/2026 |
| formoterol fumarate | Inhalation, powder for | 12 microgram | Current | Unavailable | Manufacturing | 17/02/2026 |
| memantine hydrochloride | Tablet, film coated | 20 mg | Anticipated | Available | Manufacturing | 17/02/2026 |
| stiripentol | Capsule | 500 mg | Anticipated | Available | Manufacturing | 17/02/2026 |
| Tiger snake antivenom~Taipan antivenom~Death adder antivenom~Brown snake antivenom~Black snake antivenom | Injection, concentrated | 3000 U~12000 U~6000 U~1000 U~18000 U | Current | Limited Availability | Manufacturing | 17/02/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Resolved | Available | Manufacturing | 17/02/2026 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/02/2026 |
| clindamycin phosphate | Injection, solution | 0 QS | Resolved | Available | Manufacturing | 17/02/2026 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 17/02/2026 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| aprepitant | Capsule | 165 mg | Current | Limited Availability | Manufacturing | 16/02/2026 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| imipramine hydrochloride | Tablet, sugar coated | 10 mg | Current | Limited Availability | Manufacturing | 16/02/2026 |
| gliclazide | Tablet, modified release | 30 mg | Anticipated | Available | Manufacturing | 16/02/2026 |
| nortriptyline | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 16/02/2026 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| solifenacin succinate | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| milrinone | Injection, concentrated | 10 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| estradiol | Drug delivery system, transdermal | .585 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| lamotrigine | Tablet, chewable | 25 mg | Resolved | Available | Manufacturing | 16/02/2026 |
| hydroxocobalamin acetate | Injection, solution | 1.044 mg | Current | Limited Availability | Unexpected increase in consumer demand | 16/02/2026 |
| olopatadine hydrochloride | Eye Drops, solution | 1.11 mg/mL | Current | Emergency Supply Only | Unexpected increase in consumer demand | 16/02/2026 |
| moxonidine | Tablet, film coated | 200 microgram | Current | Limited Availability | Manufacturing | 16/02/2026 |
| cyproterone acetate | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 16/02/2026 |
| rosuvastatin calcium | Tablet, film coated | 20.84 mg | Current | Limited Availability | Manufacturing | 16/02/2026 |
| pioglitazone hydrochloride | Tablet | 49.9 mg | Current | Limited Availability | Manufacturing | 16/02/2026 |
| metronidazole | Tablet, uncoated | 400 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/02/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| live varicella vaccine | Injection, powder for | 2700 PFU/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 16/02/2026 |
| isotretinoin | Capsule, soft | 20 mg | Current | Unavailable | Manufacturing | 16/02/2026 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~40 mg | Resolved | Available | Manufacturing | 16/02/2026 |
| framycetin sulfate~gramicidin~dexamethasone | Ear Drops | 5 mg/mL~.05 mg/mL~.5 mg/mL | Resolved | Available | Manufacturing | 16/02/2026 |
| metronidazole | Tablet, uncoated | 400 mg | Resolved | Available | Manufacturing | 16/02/2026 |
2026年2月23日